Targeting MUC1-C with an antibody-drug conjugate (M1C ADC) is effective against NSCLC HCC827 cells with an activating EGFR(del E746-A750) mutation sensitive to TKIs growing in vitro and as tumor xenografts.60 However, it is not known if the M1C ADC is active in settings of NSCLC TKI resistance. This evidence concerns the gene MUC1 and neoplasm.